Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Holdings Increased by Jane Street Group LLC

Jane Street Group LLC lifted its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 78.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,193 shares of the company’s stock after purchasing an additional 17,215 shares during the quarter. Jane Street Group LLC owned 0.09% of Kyverna Therapeutics worth $192,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Deerfield Management Company L.P. Series C grew its position in Kyverna Therapeutics by 35.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock valued at $14,872,000 after buying an additional 520,663 shares in the last quarter. Novo Holdings A S boosted its holdings in shares of Kyverna Therapeutics by 5.7% in the third quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock valued at $9,046,000 after acquiring an additional 100,000 shares in the last quarter. Millennium Management LLC increased its stake in shares of Kyverna Therapeutics by 32.8% during the second quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock valued at $6,923,000 after acquiring an additional 227,988 shares during the period. Great Point Partners LLC raised its holdings in Kyverna Therapeutics by 232.8% during the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock worth $3,744,000 after purchasing an additional 349,152 shares in the last quarter. Finally, MBB Public Markets I LLC acquired a new stake in Kyverna Therapeutics in the second quarter worth approximately $3,076,000. 18.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KYTX has been the topic of a number of research reports. Rodman & Renshaw began coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 price objective on the stock. RODMAN&RENSHAW raised shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. HC Wainwright reduced their price objective on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. UBS Group initiated coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 target price for the company. Finally, Wells Fargo & Company decreased their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.71.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX opened at $3.45 on Monday. The firm has a 50 day simple moving average of $4.51 and a 200 day simple moving average of $6.13. Kyverna Therapeutics, Inc. has a 52 week low of $3.41 and a 52 week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter. As a group, analysts expect that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.